Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2025

Genmab — Januar 2025

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #38

    Rybrevant https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-plus-lazcluze-130000654.html

    1 Reply Last reply
    0
    • Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktør
      wrote on sidst redigeret af
      #39

      J&J's Rybrevant, Lazcluze combo significantly improves survival over Tagrisso in lung cancer https://firstwordpharma.com/story/5925447

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #40

        quite a few cancer centers in Asia added to the Acasunlimab /Pembro Ph3 trial. maybe the local presence/office in Japan helps here. a bit surprised they still name Biontech as Collaborator. https://clinicaltrials.gov/study/NCT06635824?tab=history&a=4&b=5#version-content-panel

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #41

          Sachin Jain

          Bank of America Securities Buy Kr.2,700.00 Reiterated Today

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #42

            Healthcare +0,6% (incl NBI +0,9%
            ) klarede sig rimeligt i et ellers ræverødt us her i aften.

            1 Reply Last reply
            0
            • A Offline
              A Offline
              Aaanditsgone
              wrote on sidst redigeret af
              #43

              Hvordan vurderer I gårsdagens Rybrevant-data? Er de ikke ret positive? Og gør det ikke GEN1286 ekstra spændende, når den ifølge Jan er meget bedre end amivantamab i prækliniske studier?

              1 Reply Last reply
              0
              • Y Offline
                Y Offline
                YPE
                wrote on sidst redigeret af
                #44

                Deadline for jnj beslutning må være 28. feb. - tror på en hurtig afklaring her i jan.

                1 Reply Last reply
                0
                • R Offline
                  R Offline
                  Raun
                  wrote on sidst redigeret af
                  #45

                  Hvis der kommer en hurtig afklaring fra JnJ. Så er det fordi de kommer med et bud på Genmab.... - Ellers er jeg ret sikker på at afklaringen bliver trukket i det længste...

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #46

                    Sachin Jain’s rating is based on Genmab’s promising pipeline and strategic developments. One of the key factors is the anticipated progress of the HexaBody-CD38, which is set for a critical opt-in decision by JNJ in the first quarter of 2025. This decision will determine the future of the drug, which has shown encouraging data in comparison to Darzalex in multiple myeloma.
                    Another significant reason for the Buy rating is the potential of Rina-S,

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #47

                      an antibody-drug conjugate targeting the folate receptor alpha. Rina-S has demonstrated a compelling safety and efficacy profile, with notable antitumor activity, positioning it as a strong competitor against existing treatments like AbbVie’s Elahere.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #48

                        Additionally, the strong launch of Epkinly in late-line patients and its promising expansion into larger indications further supports the Buy recommendation. The company’s confidence in managing liver toxicity issues related to Acasunlimab and the robust overall survival data add to the optimistic outlook for Genmab.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #49

                          CLL is Still in Retreat on My Epcoritamab Trial https://cllsociety.org/2025/01/cll-is-still-in-retreat-on-my-epcoritamab-trial/

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            lahn1
                            wrote on sidst redigeret af
                            #50

                            Dejligt med positive patienthistorier 🙂

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #51

                              another small new trial - Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma https://clinicaltrials.gov/study/NCT06575686

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #52

                                January 8, 2025
                                H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $50.00 price target on Genmab https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Genmab+AS+(GMAB)/24184756.html

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #53

                                  TD Cowen maintains
                                  a hold

                                  1 Reply Last reply
                                  0
                                  • V Offline
                                    V Offline
                                    Vitus
                                    wrote on sidst redigeret af
                                    #54

                                    Kurs 1600 er en hurdle !

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #55

                                      ja nedefra og op:-)

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #56

                                        Godmorgen 🙂

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Stroka
                                          wrote on sidst redigeret af
                                          #57

                                          God morgen 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper